| 000 | 01754 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250513152656.0 | ||
| 264 | 0 | _c19981016 | |
| 008 | 199810s 0 0 eng d | ||
| 022 | _a0036-8075 | ||
| 024 | 7 |
_a10.1126/science.282.5386.103 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aNeumann, A U | |
| 245 | 0 | 0 |
_aHepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. _h[electronic resource] |
| 260 |
_bScience (New York, N.Y.) _cOct 1998 |
||
| 300 |
_a103-7 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 |
_aAlanine Transaminase _xblood |
| 650 | 0 | 4 |
_aAntiviral Agents _xadministration & dosage |
| 650 | 0 | 4 | _aCell Death |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aHalf-Life |
| 650 | 0 | 4 |
_aHepacivirus _xphysiology |
| 650 | 0 | 4 |
_aHepatitis C _ximmunology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInterferon alpha-2 |
| 650 | 0 | 4 |
_aInterferon-alpha _xadministration & dosage |
| 650 | 0 | 4 | _aKinetics |
| 650 | 0 | 4 | _aModels, Biological |
| 650 | 0 | 4 |
_aRNA, Viral _xblood |
| 650 | 0 | 4 | _aRecombinant Proteins |
| 650 | 0 | 4 | _aRegression Analysis |
| 650 | 0 | 4 | _aViral Load |
| 650 | 0 | 4 |
_aViremia _xvirology |
| 650 | 0 | 4 |
_aVirion _xphysiology |
| 650 | 0 | 4 | _aVirus Replication |
| 700 | 1 | _aLam, N P | |
| 700 | 1 | _aDahari, H | |
| 700 | 1 | _aGretch, D R | |
| 700 | 1 | _aWiley, T E | |
| 700 | 1 | _aLayden, T J | |
| 700 | 1 | _aPerelson, A S | |
| 773 | 0 |
_tScience (New York, N.Y.) _gvol. 282 _gno. 5386 _gp. 103-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1126/science.282.5386.103 _zAvailable from publisher's website |
| 999 |
_c9721363 _d9721363 |
||